How many clinical trials are there for Immune System Diseases?

PlainTrial tracks 19 US clinical trials for Immune System Diseases, of which 6 are currently recruiting.

Which interventions appear most often on Immune System Diseases trial records?

Fludarabine is the most-linked intervention name on Immune System Diseases records (4 trial links), followed by Bendamustine. Names are sponsor-reported on ClinicalTrials.gov.

How do I find a recruiting trial for Immune System Diseases?

Use the trial list filtered by Recruiting status, or visit the trial finder to search by condition and state. Always discuss with your healthcare provider.

Is this data current?

Data is from ClinicalTrials.gov. Trial status may have changed. Always verify at ClinicalTrials.gov before making participation decisions.

Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

Immune System Diseases: early-phase trial registry

Compiled by PlainTrial · August 8, 2026

6 of 19 indexed Immune System Diseases trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #902 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

19 US clinical trials · 6 currently recruiting · #902 of 28,707 conditions by registered trial count

Immune System Diseases: 19 US clinical trials tracked, 6 recruiting.

Immune System Diseases is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is UNC Lineberger Comprehensive Cancer Center, running 7 of these trials.

Enrollment posture brief

Registry condition immune-system-diseases

Volume-matched condition peers

Nearest open-share peer: Back Pain (32% recruiting · 38 trials)

Open-enrollment share among volume-matched conditions near Immune System Diseases

Immune System Diseases lists 6 open slots (32% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Immune System Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

Immune System Diseases is recruiting below its size-band peers.

6 of 19 indexed trials (31.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
One sponsor concentrates Immune System Diseases research.

UNC Lineberger Comprehensive Cancer Center accounts for 7 of 19 trials (36.8%). 9 distinct sponsors appear on at least one study for this condition label.
Most Immune System Diseases trials plan to enrol fewer than 100 people.

Median target enrolment is 43 among the 19 trials that report a genuine target (sentinel values excluded). 15 of those (78.9%) plan for fewer than 100 participants.
Immune System Diseases research is mostly interventional.

15 interventional and 4 observational studies make up this index (78.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Open and recent trials

19 total, page 1 of 1

RECRUITING 800 participants

Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00001406

RECRUITING 600 participants

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00006150

RECRUITING Phase 2 354 participants

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

National Cancer Institute (NCI)

NCT02579967

RECRUITING Phase 2 330 participants

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

National Cancer Institute (NCI)

NCT03922724

RECRUITING Phase 2 66 participants

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

National Cancer Institute (NCI)

NCT04339777

RECRUITING Phase 2 39 participants

A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

Memorial Sloan Kettering Cancer Center

NCT05787574

ACTIVE NOT RECRUITING Phase 2 90 participants

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Aravax Pty

NCT05621317

ACTIVE NOT RECRUITING Phase 2 71 participants

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

National Cancer Institute (NCI)

NCT03663933

ACTIVE NOT RECRUITING Phase 1 43 participants